Author

T. Wilhelm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. Arock· 2 shared M. Huber· 2 shared A. Crane· 1 shared A. Kaiser· 1 shared A. Scelfo· 1 shared A. Smogorzewska· 1 shared B. Kim· 1 shared B. Raught· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Arock

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

KIRA6 is an effective and versatile mast cell inhibitor of IgE-mediated activation

T. Wilhelm, V. Wunderle, S. Boukeileh, J. Gossen, M. A. Margreiter, R. Sakurov, S. Capellmann, M. Schwoerer, N. Ahmed, G. Bronneberg, M. Arock, C. Martin, T. Schubert, F. Levi-Schaffer, G. Rossetti, , M. Huber

This study identifies KIRA6 as a dual inhibitor of LYN and FYN that suppresses IgE-mediated mast cell activation and inflammation.

bioRxiv · Apr 18, 2024Immunology

Aberrant DNA repair is a vulnerability in histone H3.3-mutant brain tumors

B. Rondinelli, G. Giacomini, S. Piquet, O. Chevallier, J. Dabin, S.-K. Bai, B. Kim, R. Siddaway, B. Raught, E. Coyaud, C.-M. Shan, R. J. D. Reid, T. Toda, R. Rothstein, T. Wilhelm, , S. E. Polo

The paper identifies aberrant DNA repair as a vulnerability in H3.3-mutant brain tumors, showing that PNKP-mediated repair is specific to mutant cells and offers therapeutic potential.

bioRxiv · Sep 29, 2022 · PreprintCancer Biology

CENP-A chromatin prevents replication stress at centromeres to avoid structural aneuploidy

S. Giunta, S. Herve, R. R. White, T. Wilhelm, M. Dumont, A. Scelfo, R. Gamba, C. K. Wong, G. Rancati, A. Smogorzewska, H. Funabiki, D. Fachinetti

This study shows that CENP-A chromatin prevents replication stress at centromeres, reducing structural aneuploidy by safeguarding DNA replication of alpha-satellite repeats.

bioRxiv · Sep 1, 2020Cell Biology

Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia

T. Wilhelm, M. A. Toledo, I. Simons, C. Stuth, V. Mohta, R. Mülfarth, M. Nitsche, K. Maschke-Neuss, S. Schmitz, A. Kaiser, M. Arock, M. Zenke, M. Huber

The paper shows that combining low-dose Ponatinib and Trametinib can overcome Imatinib resistance in mast cell leukemia by inhibiting paradoxical MAPK pathway activation.

bioRxiv · Aug 31, 2020Cancer Biology